Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 3/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | BLM | P54132 | 2/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.57 |
| ▸ | RECQL | P46063 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | PKM | P14618 | 2/20 | 0.57 |
| ▸ | RGS12 | O14924 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CASP1 | P29466 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12375142 | 1.00 | USP2 (0.57) | USP2ALOX15HSD17B10KDM4ECYP3A4 | |
| SCHEMBL1577675 | 1.00 | USP2 (0.57) | USP2ALOX15HSD17B10KDM4ECYP3A4 | |
| Bromide SCHEMBL865648 | 0.98 | USP2 (0.56) | USP2ALOX15HSD17B10KDM4ECYP3A4 | |
| Bromide SCHEMBL865649 | 0.98 | USP2 (0.56) | USP2ALOX15HSD17B10KDM4ECYP3A4 | |
| SCHEMBL26664897 | 0.93 | USP2 (0.50) | USP2ALOX15HSD17B10KDM4ECYP3A4 | |
| SCHEMBL15130503 | 0.87 | ALOX15 (0.57) | USP2ALOX15HSD17B10KDM4ECYP3A4 | |
| SCHEMBL322219 | 0.87 | ALOX15 (0.57) | USP2ALOX15HSD17B10KDM4ECYP3A4 | |
| SCHEMBL5981375 | 0.87 | ALOX15 (0.57) | USP2ALOX15HSD17B10KDM4ECYP3A4 | |
| SCHEMBL15130505 | 0.87 | ALOX15 (0.57) | USP2ALOX15HSD17B10KDM4ECYP3A4 | |
| SCHEMBL19501942 | 0.87 | ALOX15 (0.57) | USP2ALOX15HSD17B10KDM4ECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094701-A | TLR3 binding bicyclic peptide ligands | — | 2026-05-26 | — | — | CN | claimed |
| WO-2025046244-A1 | TLR3 BINDING BICYCLIC PEPTIDE LIGANDS | BICYCLETX LIMITED (GB) | 2025-03-06 | — | — | WO | claimed |
| EP-4274838-B1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS | BICYCLETX LTD (GB) | 2024-09-25 | — | — | EP | claimed |
| US-20240108738-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS | BICYCLETX LIMITED (GB) | 2024-04-04 | — | — | US | claimed |
| CN-117529489-A | Bicyclic peptide ligands specific for NK cells | 拜斯科技术开发有限公司 | 2024-02-06 | — | — | CN | claimed |
| EP-4274838-A2 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS | BicycleTx Limited (GB) | 2023-11-15 | — | — | EP | claimed |
| WO-2022148974-A2 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS | BICYCLETX LIMITED (GB) | 2022-07-14 | — | — | WO | claimed |
| US-11053249-B2 | Proteasome inhibiting β-lactam prodrugs useful for the treatment of cancer and neurodegenerative disorders | PHILIPPE YVES-REMY SIMON (FR) | 2021-07-06 | — | — | US | claimed |
| US-20200216455-A1 | Proteasome Inhibiting Beta-Lactam Produrgs Useful for the Treatment of Cancer and Nurodegenerative Disorders | VITA API (FR) | 2020-07-09 | — | — | US | claimed |
| CN-110885358-A | Vaccine for preventing tumor recurrence and metastasis and application method thereof | 浙江爱睦世医学科技有限公司 | 2020-03-17 | — | — | CN | claimed |
| CN-110857314-A | Active polypeptide, polypeptide derivative, composition and using method thereof | 许洋 | 2020-03-03 | — | — | CN | claimed |
| WO-2018115497-A1 | PROTEASOME INHIBITING ß-LACTAM PRODRUGS USEFUL FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS | VITA API (FR) | 2018-06-28 | — | — | WO | claimed |
| EP-3339291-A1 | PROTEASOME INHIBITING SS-LACTAM PRODRUGS USEFUL FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS | VITA API (FR) | 2018-06-27 | — | — | EP | claimed |
| EP-2876165-A1 | Improved method for producing modifed target polypeptides | ACIB GmbH (AT) | 2015-05-27 | — | — | EP | claimed |
| US-20050137421-A1 | Method for making fluorine labled L-Dopa | CTI PET SYSTEMS, INC. | 2005-06-23 | — | — | US | claimed |
| CN-122094701-A | TLR3 binding bicyclic peptide ligands | — | 2026-05-26 | — | — | CN | disclosed |
| CN-119120437-B | Tyrosine phenol lyase mutant and application thereof in synthesis of tyrosine derivatives | 浙江工业大学 | 2025-10-28 | — | — | CN | disclosed |
| WO-2003018553-A1 | ORAL ANTIDIABETIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2003-03-06 | — | — | WO | disclosed |
| US-5254726-A | Reacting aromatic nitroaldehydes having protected hydroxyl groups with labeled fluoride ion | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF ENERGY (US) | 1993-10-19 | — | — | US | disclosed |
| US-4925651-A | TUMOR DIAGNOSIS | KERNFORSCHUNGSANLAGE JUELICH GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1990-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108738-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS | PBK, KLRK1, MICA | USP2 4659/4885ALOX15 1994/4885HSD17B10 4416/4885 |
| US-11053249-B2 | Proteasome inhibiting β-lactam prodrugs useful for the treatment of cancer and neurodegenerative disorders | PSMB5, PSMB1, PSMB11 | USP2 102/4885ALOX15 2434/4885HSD17B10 1893/4885 |
| US-20050137421-A1 | Method for making fluorine labled L-Dopa | MAOB, DBH, MAOA | USP2 3634/4885ALOX15 129/4885HSD17B10 1077/4885 |
| US-20200216455-A1 | Proteasome Inhibiting Beta-Lactam Produrgs Useful for the Treatment of Cancer and Nurodegenerative Disorders | PSMB5, PSMB1, PSMB11 | USP2 129/4885ALOX15 2878/4885HSD17B10 1810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.